A Pilot Study of Raltegravir and Cisplatin in Squamous Cell Carcinoma of the Head and Neck
Phase of Trial: Phase 0
Latest Information Update: 22 Jun 2015
At a glance
- Drugs Cisplatin (Primary) ; Raltegravir (Primary) ; Docetaxel
- Indications Head and neck cancer
- Focus Pharmacodynamics; Pharmacogenomic
- 17 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 13 Aug 2013 Planned end date changed from 1 May 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 19 Feb 2013 Planned end date changed from 1 Dec 2013 to 1 May 2014 as reported by ClinicalTrials.gov.